Adicet Bio (ACET) vs iBio (IBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
iBio (IBIO) has outperformed Adicet Bio (ACET) over the past year, gaining 5.7% versus a loss of 61.4%. Over five years, ACET leads with a -95.5% price change compared with -99.8% for IBIO. iBio is the larger company by market cap ($56.0 million vs $52.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | IBIO |
|---|---|---|
| Share price | $5.61 | $0.871 |
| Market cap | $52.52M | $56.01M |
| 1-day change | -2.26% | -5.33% |
| YTD return | -31.83% | -52.33% |
| 1-year return | -61.38% | +5.75% |
| 5-year return | -95.54% | -99.80% |
| EPS (TTM) | $-10.42 | $-0.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.44 | $3.82 |
| 52-week low | $5.55 | $0.78 |
| Distance from 52-week high | -67.83% | -77.20% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +520.86% | +553.27% |
| Average volume | 172.38K | 727.93K |
| Shares outstanding | 9.36M | 64.31M |
| Employees | 102 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBIO has outperformed ACET by 67.1 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
About iBio
IBIO stock →iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
ACET vs IBIO FAQ
Which is bigger, Adicet Bio or iBio?
iBio (IBIO) is larger, with a market capitalization of $56.01M compared with $52.52M for Adicet Bio (ACET).
Which stock has performed better over the past year, ACET or IBIO?
IBIO returned +5.75% over the past 12 months, compared with -61.38% for ACET (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and iBio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.